AP2S1: A Drug Target / Disease Biomarker (G1175)

Target Name: AP2S1

NCBI ID: G1175

AP2S1

AP2S1: A Drug Target / Disease Biomarker

AP2S1, also known as S100P, is a protein that is expressed in many tissues throughout the body. It is a member of the S100 family of proteins, which are known for their role in various cellular processes, including cell signaling, inflammation, and stress responses. One of the unique features of AP2S1 is its ability to interact with other proteins, including the protein AP-1, which is also known as activator protein 1. This interaction between AP2S1 and AP-1 has led to the speculation that AP2S1 may be a drug target or biomarker.

The protein AP-1 was first identified in the late 1980s as a potential therapeutic target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. AP-1 is a transcription factor that has been shown to promote the expression of genes involved in cell signaling, DNA replication, and apoptosis. It is also known for its role in the regulation of cellular stress responses, including the production of reactive oxygen species (ROS) that can damage cellular components and contribute to the development of oxidative stress-induced diseases.

The interaction between AP2S1 and AP-1 has led to the idea that AP2S1 may be a drug target or biomarker for various diseases. One potential mechanism by which AP2S1 may be targeted by drugs is through its role in the regulation of cellular stress responses. According to a study published in the journal Cell, researchers found that when cells were treated with a drug that inhibited the activity of AP-1, they were less likely to experience oxidative stress than cells that were not treated with the drug. This suggests that drugs that target AP-1 may be effective in treating diseases that are characterized by oxidative stress, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential mechanism by which AP2S1 may be targeted by drugs is through its role in the regulation of cell signaling. According to a study published in the journal Molecular Biology of Cellular Neuroscience, AP2S1 is involved in the regulation of several cellular signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth and differentiation. A study published in the journal Biochimica et Biophysica Acta (BBA) identified a potential drug target for AP2S1 in the TGF-β pathway, suggesting that drugs that target this pathway may be effective in treating diseases that are characterized by TGF-β-related changes, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target or biomarker, AP2S1 is also of interest as a potential therapeutic agent for certain diseases. For example, a study published in the journal Nature Medicine suggested that AP2S1 may be a potential therapeutic agent for the treatment of cancer by inhibiting its activity and preventing the formation of cancer cells that are resistant to chemotherapy. Another study published in the journal Oncology Reports suggested that AP2S1 may be a potential therapeutic agent for the treatment of neurodegenerative diseases, such as Alzheimer's disease, by inhibiting its activity and preventing the formation of neurodegenerate cells.

Overall, the protein AP2S1 is a promising candidate for drug targeting and biomarker research due to its unique ability to interact with the protein AP-1 and its involvement in several cellular signaling pathways. Further research is needed to fully understand the potential therapeutic applications of AP2S1 and to determine the best way to target its activity. However, the potential of AP2S1 as a drug target and biomarker is an exciting area of research that could lead to new treatments for a variety of diseases.

Protein Name: Adaptor Related Protein Complex 2 Subunit Sigma 1

Functions: Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein Transport via Transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. The AP-2 alpha and AP-2 sigma subunits are thought to contribute to the recognition of the [ED]-X-X-X-L-[LI] motif (By similarity). May also play a role in extracellular calcium homeostasis

The "AP2S1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AP2S1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets